Company Overview and News

 
Hong Kong stocks rise modestly after Trump comments on trade talks temper optimism over Fed rate increases

2018-05-25 scmp
The Hong Kong stock market closed higher, with a tepid turnover, after a choppy session on Thursday, as optimism that the US Federal Reserve was unlikely to accelerate the pace of interest rate increases was offset by comments made by US President Donald Trump, which suggested a setback in the US-China trade talks.

 
Insurers lead Hong Kong stocks higher in morning session

2018-05-08 scmp
Hong Kong stocks began the morning session higher on Tuesday, driven by gains in insurers and overnight advances in Wall Street as investors await a decision by the US to reimpose sanctions on Iran.

2
Geely Automobile and Agile Group have a big week as directors accumulate shares

2018-05-06 scmp
There were several significant transactions last week with insider buys in Geely Automobile Holdings and Agile Group. There was also a rare purchase by the CEO and buy-back in VSTECS Holdings.

 
In remote China, a high-tech auto plant flags global challenge

2018-04-27 reuters
ZHANGJIAKOU, China (Reuters) - While auto workers in Germany and South Korea fight to save their jobs, one of China’s youngest auto brands is gearing up to build sport utility vehicles at a new factory with digitally-connected robots and a fresh workforce of 1,800 people.

 
Hostile takeover? Daimler CEO says no fears about Chinese magnate Li Shufu

2018-04-25 channelnewsasia
German car maker Daimler AG's boss said on Wednesday there was no indication the firm's largest shareholder, Chinese auto magnate Li Shufu, was planning a hostile takeover, after he took a US$9 billion stake in the firm earlier this year.

 
Daimler CEO: no sign of hostile takeover by top shareholder Li Shufu

2018-04-25 channelnewsasia
German car maker Daimler AG's boss said on Wednesday there was no indication the firm's largest shareholder, Chinese auto magnate Li Shufu, was planning a hostile takeover, after he took a US$9 billion stake in the firm earlier this year.

 
China carmaker GAC says trade war could hurt plans to enter U.S. market

2018-04-25 reuters
BEIJING (Reuters) - Guangzhou Automobile Group Co Ltd (GAC) (601238.SS) on Wednesday said a brewing trade war between China and the United States could hurt the Chinese automaker’s plans to break into the U.S. market if tariff barriers were raised.

 
AUTOSHOW-China carmaker GAC says trade war could hurt plans to enter U.S. market

2018-04-25 reuters
BEIJING, April 25 (Reuters) - Guangzhou Automobile Group Co Ltd (GAC) on Wednesday said a brewing trade war between China and the United States could hurt the Chinese automaker’s plans to break into the U.S. market if tariff barriers were raised.

 
Geely-Aisin Seiki JV to produce automatic transmissions in China

2018-04-25 reuters
HONG KONG (Reuters) - Geely Automobile Holdings Ltd (0175.HK) said on Wednesday it would team up with Japanese automobile transmissions maker Aisin Seiki Co Ltd (7259.T) to manufacture front-wheel drive 6-speed automatic transmissions and related components in China.

1
Shares of Chinese carmakers plunge as Beijing moves to fully open market to foreign ventures

2018-04-18 scmp
Credit Suisse slashes stock price targets of a few major players as the bargaining power of local partners will be reduced because of the policy changes

 
China’s WM Motor bets on factory expansion in push to get ahead in electric car market 

2018-04-16 scmp
The company will be entering a crowded field with a lot of local competitors, but says it plans to be the first to deliver vehicles on a mass scale

 
Hong Kong's Most Painful Short Keeps on Breaking Record Highs - Bloomberg

2018-04-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Tesla and China trade war: Elon Musk has tough tariff riddle to solve

2018-04-04 cnbc
Tesla founder and CEO Elon Musk has long believed China will be a huge driver of electric vehicle sales, even outranking the U.S. one day. Wall Street analysts have expressed the same belief. But as the trade war between the U.S. and China intensifies, Musk finds himself on both sides of the divide. The Chinese government is doing much more to support EVs than the U.S. government right now, but the tariffs that Tesla and other foreign automakers pay to sell in the Chinese market are steep.

 
Tariffs Seek to End Chinese Car Imports Before They Really Start - Bloomberg

2018-04-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
DRB Hicom-Geely partnership promises exciting future, say dealers

2018-04-02 themalaymailonline
The Geely Automobile Holdings logo is pictured at the Auto China 2016 auto show in Beijing, China April 25, 2016. — Reuters picKUALA LUMPUR, April 2 — The partnership between DRB-HICOM Bhd and Zhejiang Geely Holding Group Co Ltd bodes well for the future, thanks to the technology and research scope developed by the Geely Research Institute (GRI), said Proton Holdings Bhd’s dealers.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...